BAXTER INTERNATIONAL INC acquires ESI Lederle (assets, from Wyeth)

BAXTER INTERNATIONAL INC acquired ESI Lederle (assets, from Wyeth) for $308M, a transaction completed in December 2002, structured as Acquisition of the majority of the assets of ESI Lederle, a division of Wyeth.

ESI Lederle (assets, from Wyeth) operates in Medication Delivery, is based in United States. Baxter acquired the majority of the assets of ESI Lederle, a division of Wyeth and a leading U.S. manufacturer and distributor of injectable generic drugs for the hospital market, offering a complete range of sterile injectable manufacturing capabilities including ampules and vials. The acquisition leveraged Baxter's injectable expertise, channel strength and manufacturing capabilities.

Expanded Baxter's injectable generic drug manufacturing capacity and U.S. hospital-market channel.

Advisory firms were not disclosed for this transaction.

You're subscribed.

Thanks for signing up.